Cardinal Health (CAH) Q4 2024: $10B New Revenue Pipeline Offsets $40B Contract Loss

August 14, 2024 | By EarningsIQ Research

Cardinal Health delivered record earnings and cash flow, navigating a $40B contract expiration with $10B in new customer commitments and specialty growth. The GMPD turnaround accelerated, and management raised both EPS guidance and share buyback plans, signaling confidence in the business model’s resilience and future cash generation. Investors should focus on the company’s ability to execute on new wins, specialty expansion, and ongoing cost discipline as secular healthcare demand and portfolio optimization drive long-term value.

Summary

  • Specialty and New Business Outpace Lost Contract: $10B in new customer wins and specialty expansion are set to offset a $40B contract expiration.
  • GMPD Turnaround and Cash Generation: Segment profit surged $240M, with further working capital actions targeting $500M in near-term cash.
  • Raised Guidance and Buybacks Signal Confidence: Management lifted EPS outlook and share repurchase plans, underpinned by robust free cash flow and operational execution.

Business Overview

Cardinal Health is a leading healthcare services and products distributor serving pharmacies, hospitals, and other care providers. The company generates revenue primarily through its Pharmaceutical and Specialty Solutions segment (drug distribution, specialty, and manufacturer solutions), GMPD (Global Medical Products and Distribution) (medical supply distribution and Cardinal Health branded products), and a portfolio of growth businesses including nuclear and precision health solutions, at-home solutions, and OptiFreight logistics. Revenue is driven by product distribution, specialty healthcare solutions, and value-added supply chain services.

Performance Analysis

Cardinal Health closed fiscal 2024 with record EPS and nearly $4B in adjusted free cash flow, demonstrating strong execution across its core and growth businesses. The Pharma and Specialty Solutions segment posted double-digit revenue growth, with specialty revenues now exceeding $36B and continuing to outpace the market. Importantly, the company managed a major $40B contract expiration, but offset much of the impact through $10B in new customer wins and specialty network expansion, underlining the business’s ability to replenish its pipeline and maintain resilience even amid large customer transitions.

GMPD delivered a $240M year-over-year profit improvement, returning to profitability and meeting inflation mitigation targets. Segment profit was supported by volume growth in Cardinal Health branded products and a disciplined cost structure, while investments in automation and domestic manufacturing improved operational flexibility. The “Other” segment, comprising at-home, nuclear, and logistics, grew revenue 15% and segment profit 11%, reflecting secular tailwinds and effective capital deployment.

  • Specialty Revenue Expansion: Specialty grew 14% YoY, now representing over $36B, with continued strength expected despite the contract loss.
  • GMPD Profitability Restoration: Segment profit improvement of $240M YoY, with further runway from simplification and working capital initiatives.
  • Shareholder Returns Accelerate: $1.25B returned in FY24; FY25 buyback plan raised to $750M, above baseline, as cash generation outpaces expectations.

Cardinal Health’s performance underscores the effectiveness of its diversified business model and disciplined capital allocation, even as macro and industry-specific headwinds persist. The company’s ability to rapidly replace lost volume, control costs, and invest in growth platforms positions it favorably for continued value creation.

Executive Commentary

"We finished the year with momentum, growing EPS 29% in both Q4 and fiscal year 24... We have managed through the transition of a significant customer and are raising our guidance for fiscal year 25, while also reconfirming our long-term financial targets."

Jason Haller, Chief Executive Officer

"We delivered strong gross margin growth and matched it with well-controlled SG&A, even in an inflationary environment... Our excellent adjusted free cash flow results in 2024 was almost entirely a result of the team's year-long effort to optimize each element of our working capital while remaining focused on our service levels."

Aaron Ault, Chief Financial Officer

Strategic Positioning

1. Pharma and Specialty: Pipeline Replenishment and Specialty Acceleration

The company’s core pharma business demonstrated resilience by offsetting a $40B contract expiration with $10B in new customer wins and expansions. Specialty remains a high-growth engine, with investments in biosimilars (Aviron joint venture), specialty networks, and advanced therapy logistics driving continued outperformance. The ability to integrate new customers and leverage specialty platforms is central to future margin and revenue growth.

2. GMPD: Turnaround, Simplification, and Cash Generation

GMPD’s $240M profit improvement and return to positive free cash flow mark a successful phase of the turnaround plan. Management is now targeting at least $500M in additional cash through working capital and simplification actions over two years. Domestic manufacturing investments and supply chain diversification are designed to mitigate tariff and freight risk while enhancing service reliability for acute care customers.

3. Growth Businesses: Capital Deployment and Secular Tailwinds

Nuclear, at-home solutions, and OptiFreight logistics are receiving targeted investments in automation, distribution, and technology. These businesses benefit from secular trends such as home-based care, precision medicine, and healthcare logistics optimization, supporting double-digit revenue and profit growth targets for FY25.

4. Portfolio Optimization and Capital Allocation Discipline

Management’s ongoing portfolio review has shifted from divestiture considerations to value-maximizing improvement plans, particularly in GMPD. The board is now directly overseeing value creation, and capital allocation remains focused on returning cash to shareholders while funding high-ROI growth investments.

Key Considerations

This quarter’s results highlight Cardinal Health’s ability to execute through disruption and reposition for growth. The strategic context is defined by the interplay between customer transitions, specialty growth, cash optimization, and targeted investments.

Key Considerations:

  • Pipeline Resilience: The company’s ability to backfill lost volume with $10B in new commitments is a critical signal of commercial strength and customer value proposition.
  • Specialty as Margin Lever: Continued double-digit specialty growth and biosimilar expansion are vital for margin stability and long-term competitive positioning.
  • GMPD Cash Generation: Additional $500M in targeted cash actions will support shareholder returns and reinvestment, but execution risk remains as working capital improvements are implemented.
  • Balanced Capital Allocation: Raised buyback guidance to $750M in FY25, reflecting confidence in cash flow durability and capital discipline.
  • Growth Business Investment: Ongoing investments in nuclear, at-home, and logistics are expected to yield above-market growth, but require continued operational focus and integration.

Risks

Execution risk is elevated as Cardinal Health manages the onboarding of large new customers and ramps specialty volumes to offset the contract expiration. Freight and input cost volatility, while currently manageable, could pressure margins if supply chain disruptions reemerge. Tariff exposure, though limited in China, remains a watchpoint across broader Asia sourcing. The company’s 1% margin structure leaves little room for operational missteps, and sustained outperformance in working capital and cost control will be necessary to deliver on raised guidance. Lastly, the transition from a business review committee to full board oversight of portfolio optimization introduces governance continuity risk.

Forward Outlook

For Q1 FY25, Cardinal Health guided to:

  • Pharma segment profit down in the first half, with growth ramping in the back half as new customer volumes scale
  • GMPD profit of up to $20M in Q1, with sequential improvement expected through the year

For full-year FY25, management raised guidance:

  • EPS range of $7.55 to $7.70
  • Pharma segment profit growth of 1% to 3%, despite $40B revenue headwind
  • GMPD segment profit target of $175M, on path to $300M by FY26
  • Other businesses targeting 10% to 12% revenue growth and ~10% profit growth

Management highlighted several factors that shape the outlook:

  • Back-end loaded profit ramp as new business and specialty contributions scale through FY25
  • Continued focus on working capital, cost optimization, and execution of growth investments

Takeaways

Cardinal Health’s multi-pronged growth and cash generation story is intact, with strategic execution offsetting significant headwinds.

  • Customer Transition Absorbed: Rapid pipeline replenishment and specialty growth are set to neutralize the impact of a $40B contract loss, validating the strength of the company’s commercial model.
  • GMPD and Cash Flow as Value Drivers: Turnaround progress and targeted working capital actions underpin enhanced buybacks and reinvestment capacity, but require sustained discipline.
  • Growth Businesses and Specialty Are the Next Leg: Investors should monitor execution in specialty, biosimilars, and growth businesses for signals of margin durability and future upside.

Conclusion

Cardinal Health delivered a record year, demonstrating operational agility and capital discipline through a period of significant transition. With specialty and growth businesses offsetting legacy customer losses, and GMPD profitability restored, the company is positioned to sustain earnings growth and shareholder returns—provided execution on new wins and cost initiatives remains robust.

Industry Read-Through

Cardinal Health’s quarter underscores the critical importance of specialty distribution, biosimilars, and value-added services as margin and growth levers in the healthcare supply chain. The company’s ability to quickly replenish lost volume and invest in automation and domestic manufacturing highlights the sector-wide need for supply chain resilience, especially as tariff and freight volatility persist. For peers, the success of targeted working capital actions and growth business investment offers a blueprint for navigating low-margin, high-volume distribution models. The ongoing shift toward home-based care, precision medicine, and logistics optimization is likely to accelerate, benefiting those with diversified platforms and capital allocation discipline. Tariff and sourcing risk remains a sector-wide concern, particularly for those with heavier China exposure.

CAH Healthcare Distribution Specialty GMPD Biosimilars Cash Flow Portfolio Optimization